Advanced search
Publication Cover
Current Medical Research and Opinion Volume 30, 2014 - Issue 10
Submit an article Journal homepage
575
Views
16
CrossRef citations to date
0
Altmetric
Brief report

Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain

Sebastiano MercadanteAnesthesia & Intensive Care and Pain Relief & Supportive Care, La Maddalena Cancer Center PalermoItaly;University of Palermo PalermoItalyCorrespondence[email protected] [email protected]
,
Giampiero PorzioHome Care Program, L’Aquila per la vita, Department of Oncology University of L’AquilaItaly
,
Claudio AdileAnesthesia & Intensive Care and Pain Relief & Supportive Care, La Maddalena Cancer Center PalermoItaly
,
Federica AielliHome Care Program, L’Aquila per la vita, Department of Oncology University of L’AquilaItaly
,
Andrea CortegianiDepartment of Biopathology, Medical and Forensic Biotechnologies (DIBIMEF), Section of Anesthesia, Analgesia, Intensive Care and Emergency, University of Palermo PalermoItaly
,
Anthony DickensonDepartment of Pharmacology, University CollegeLondon
&
Alessandra CasuccioDepartment of Sciences for Health Promotion and Mother–Child Care ‘G. D’Alessandro’ University of PalermoItaly
 show all
Pages 2063-2068 | Accepted 10 Jun 2014, Published online: 27 Jun 2014

References

  • Mercadante S, Fulfaro F. World Health Organization guideline: a reappraisal. Ann Oncol 2005;16(Suppl 4):iv132-5
  • Shafer M. Novel concepts for analgesia in severe pain: current strategies and future innovations. Eur J Pain 2009;(Suppl 3):6-10
  • Cristoph T, De Vry J, Tzeschentke TM. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neurosci Lett 2010;470:91-4
  • Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Exp Opin Pharmacother 2010;11:1787-814
  • Schroder W, De Vry J, Tzeschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010;14:814-21
  • Riemsma R, Forbes C, Harker J, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 2011;27:1907-30
  • Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68
  • Mercadante S, Porzio G, Ferrera P, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 2012;28:1775-9
  • Imanaka K, Tominaga Y, Etropolski M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin 2013;29:1399-409
  • Mercadante S, Ferrera P, Villari P, et al. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009;37:632-41
  • Christoph T, De Vry J, Schiene K, et al. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. Eur J Pharmacol 2011;666:72-9
  • Mercadante S, Porzio G, Aielli F, et al. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin 2013;29:661-6
  • Mercadante S, Dardanoni G, Salvaggio L, et al. Monitoring of opioid therapy in advanced cancer pain patients. J Pain Symptom Manage 1997;13:204-12
  • Bee LA, Bannister K, Rahman W, Dickenson AH. Mu-opioid and noradrenergic α2-adrenoreceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 2011;152:131-9
  • Kress HG, Koch ED, Kosturski H, et al. Efficacy and safety of oral tapentadol extended release for the management of moderate to severe, chronic malignant tumor-related pain. Presented at ASRA 11th annual meeting, 12–15 November 2012, Miami, FL, USA
  • Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med 2011;25:494-503
  • Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 2011;25:504-15
  • Pergolizzi J, Alegre C, Blake D, et al. Current considerations for the treatment of severe chronic pain: the potential for tapentadol. Pain Pract 2012;12:290-306

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.